Yet another meta-analysis confirms the effectiveness of BioGaia’s probiotic in infantile colic

In a newly presented systematic review the proof of effect on infantile colic
was further strengthened for L. reuteri Protectis. The review is the eighth meta
-analysis evaluating L. reuteri Protectis’ effect on infantile colic.
Prior to the new review seven meta-analyses, evaluating different probiotics as
well as non-probiotic treatments, have come to the same conclusion; that L.
reuteri Protectis is effective in reducing crying time in colicky infants,
especially in breastfed and mixed fed infants.

In the new, eighth review, with four studies on L. reuteri Protectis included,
the proof was further strengthened. It combined raw data from these trials
(Individual Participant Data Meta-Analysis, IPDMA), a method that yields more
reliable estimates of treatment effect compared to traditional meta-analyses
based on published data only. The analysis was undertaken according to the
methods recommended by Cochrane (http://www.cochrane.org/about-us).

”A meta-analysis is considered the highest level of evidence of a health effect
and now there are eight such meta-analyses with BioGaia ProTectis. While this
clearly confirms BioGaia ProTectis as the number one treatment for infants with
colic, it also reassures health care professionals around the world that they
are suggesting an effective treatment when recommending BioGaia ProTectis drops
to their patients”, says Axel Sjöblad, Managing Director, BioGaia.

The systematic review and meta
-analysis (http://www.abstracts2view.com/pas/view.php?nu=PAS16L1_2710.4) was
presented at the PAS (Pediatric Academic Societies) meeting in Baltimore, USA, 1
May 2016.

Latest press releases from BioGaia
2016-04-27 BioGaia guarantees rights issue in IBT
2016-04-27 IBT’s results for the first quarter of 2016
2016-04-25 BioGaia’s oral health probiotics to be launched in Hong Kong

BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 2 May 2016, 10:00 am
CET.
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com